Income StatementBalance SheetCash FlowSegments
McKesson logo

McKesson Business Segments

Business, geographic, and product segment breakdowns

McKesson generates $403.43B in annual revenue across 4 key segments: Medical-Surgical Solutions (0), North American Pharmaceutical (0), Oncology & Multispecialty (0.1), and Prescription Technology Solutions (0.6). The company-wide operating margin is 1.54%. Based on the Q1 2026 filing.

Medical-Surgical Solutions (TTM)0.05North American Pharmaceutical (TTM)0.01Oncology & Multispecialty (TTM)0.07Prescription Technology Solutions (TTM)0.64
Latest FilingQ1 2026
Report Date2026-05-08
Market Cap$93.3B
P/E Ratio19.59
ROE-224.31%

Products & Services

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Shipping and handling costs$275.0M$275.0M$300.0M$300.0M$300.0M$300.0M

Geographic

Estimated loss

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
All Sites Excluding New Jersey—————$27.0M

Hazardous substance sites

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
All Sites Excluding New Jersey——2.752.752.752.75

Total long-lived assets

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Foreign—$306.0M$330.0M$261.0M$254.0M$255.0M

Business Segments

Asset impairments and accelerated depreciation

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Medical-Surgical Solutions$6.0M$8.0M$0.0$0.0-$11.0M—
North American Pharmaceutical$1.0M——$1.0M$1.0M—

Exit and other-related costs

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Medical-Surgical Solutions$19.0M$28.0M$12.0M$14.0M$2.0M$9.0M
North American Pharmaceutical$1.0M——$1.0M$0.0—

Foreign currency translation adjustments, net

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
North American Pharmaceutical-$20.0M-$20.0M$11.0M$11.0M$11.0M$11.0M
Medical-Surgical Solutions$0.0$0.0$0.0$0.0$0.0$0.0
Oncology & Multispecialty$0.0$0.0$0.0$0.0$0.0$0.0
Prescription Technology Solutions$0.0$0.0$0.0$0.0$0.0$0.0

Goodwill

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Oncology & Multispecialty—$2.7B—$3.9B$4.0B$4.0B
North American Pharmaceutical—$2.7B—$2.8B$2.8B$2.8B
Medical-Surgical Solutions$2.5B$2.5B$2.5B$2.5B$2.5B$2.5B
Prescription Technology Solutions$2.0B$2.0B$2.1B$2.1B$2.1B$2.1B

Goodwill acquired

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Oncology & Multispecialty$0.0$0.0$316.5M$316.5M$316.5M$316.5M
Medical-Surgical Solutions$0.0$0.0$0.0$0.0$0.0$0.0
North American Pharmaceutical$250.0K$250.0K$0.0$0.0$0.0$0.0
Prescription Technology Solutions$2.8M$2.8M$39.0M$0.0$0.0$0.0

Goodwill, transfer to held-for-sale

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Oncology & Multispecialty$0.0$0.0$2.3M$2.3M$2.3M$2.3M
Medical-Surgical Solutions$0.0$0.0$0.0$0.0$0.0$0.0
North American Pharmaceutical$11.5M$11.5M$0.0$0.0$0.0$0.0
Prescription Technology Solutions$0.0$0.0$0.0$0.0$0.0$0.0

Non-cash charges

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Medical-Surgical Solutions$6.0M$8.0M$0.0$0.0$11.0M-$19.0M
Prescription Technology Solutions$0.0$7.0M$0.0$0.0$0.0$17.0M
North American Pharmaceutical$14.5M$14.5M$3.0M$3.0M$3.0M$3.0M

Other

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Medical-Surgical Solutions-$2.0M$0.0$500.0K$500.0K$500.0K$500.0K
North American Pharmaceutical-$1.3M-$1.3M-$250.0K-$250.0K-$250.0K-$250.0K
Oncology & Multispecialty-$250.0K-$250.0K$0.0$0.0$0.0$0.0
Prescription Technology Solutions$0.0-$1.0M$0.0$0.0$0.0$0.0

Other adjustments

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Oncology & Multispecialty-$12.8M-$12.8M-$4.5M-$4.5M-$4.5M-$4.5M
Prescription Technology Solutions-$2.0M-$2.0M$0.0$0.0$0.0-$1.0M
Medical-Surgical Solutions-$7.3M-$7.3M$0.0$0.0$0.0$0.0
North American Pharmaceutical$1.3M$1.3M$0.0$0.0$0.0$0.0

Payments for Restructuring

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Medical-Surgical Solutions$44.0M$48.0M$50.0M$37.0M$43.0M$3.0M
North American Pharmaceutical$2.0M$2.0M$1.0M$1.0M$1.0M$1.0M
Oncology & Multispecialty$500.0K$500.0K$0.0$0.0$0.0$0.0
Prescription Technology Solutions$2.0M$0.0$0.0$1.0M$0.0$0.0

Restructuring Charges

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Prescription Technology Solutions$0.0$7.0M$0.0$0.0$0.0$20.0M
Medical-Surgical Solutions$19.0M$35.0M$17.0M$19.0M-$3.0M$10.0M
North American Pharmaceutical$2.0M——$6.0M$1.0M—

Revenue derived from services (less than) (as a percent)

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Medical-Surgical Solutions0.01—0.010.010.01—
North American Pharmaceutical0.01——0.010.01—
Oncology & Multispecialty0.07——0.070.07—
Prescription Technology Solutions0.36—0.380.370.36—

Separation costs

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Medical-Surgical Solutions——$13.0M$13.0M$13.0M$13.0M

Severance and employee-related costs, net

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Medical-Surgical Solutions-$6.0M$0.0$5.0M$5.0M$6.0M—
North American Pharmaceutical$0.0——$4.0M$0.0—

Subtotal

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Prescription Technology Solutions$219.0M$248.0M$253.0M$244.0M$261.0M$286.0M
Medical-Surgical Solutions$269.0M$231.0M$221.0M$220.0M$265.0M$232.0M
North American Pharmaceutical$744.0M——$852.0M$1.1B—
Oncology & Multispecialty$202.0M——$332.0M$304.0M—

Total other segment expense, net

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Medical-Surgical Solutions$2.7B$2.6B$2.5B$2.7B$2.7B$2.6B
Prescription Technology Solutions$1.2B$1.1B$1.2B$1.1B$1.2B$1.2B
North American Pharmaceutical$80.5B——$85.6B$87.3B—
Oncology & Multispecialty$9.3B——$11.7B$12.7B—

Total reserve balance

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
North American Pharmaceutical—$11.0M—$14.0M$14.0M$18.0M
Medical-Surgical Solutions$111.0M$90.0M$57.0M$39.0M$6.0M$10.0M
Prescription Technology Solutions$2.0M$1.0M$1.0M$0.0$0.0$3.0M

Total revenues

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Medical-Surgical Solutions$2.9B$2.9B$2.7B$2.9B$3.0B$2.9B
Prescription Technology Solutions$1.4B$1.3B$1.4B$1.4B$1.5B$1.5B
North American Pharmaceutical$81.2B——$86.5B$88.3B—
Oncology & Multispecialty$9.5B——$12.0B$13.0B—

Total segment depreciation and amortization

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Medical-Surgical Solutions$23.0M$25.0M$22.0M$23.0M$26.0M$25.0M
Prescription Technology Solutions$22.0M$21.0M$21.0M$20.0M$21.0M$20.0M
North American Pharmaceutical$33.0M——$32.0M$34.0M—
Oncology & Multispecialty$37.0M——$71.0M$63.0M—

Total segment expenditures for long-lived assets

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Medical-Surgical Solutions$36.0M——$32.0M$24.0M—
North American Pharmaceutical$62.0M——$74.0M$84.0M—
Oncology & Multispecialty$27.0M——$23.0M$17.0M—
Prescription Technology Solutions$3.0M——$0.0$1.0M—

Allowance for credit loss, writeoff

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
North American Pharmaceutical$59.3M$59.3M$120.8M$120.8M$120.8M$120.8M

Antitrust legal settlements

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
North American Pharmaceutical$31.0M——$0.0$15.0M—

Charges (credits) associated with last-in, first-out inventory method

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
North American Pharmaceutical$89.0M———-$10.0M—

Provision (credit) for bad debts

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
North American Pharmaceutical——-$52.5M-$52.5M-$52.5M-$52.5M

Receivables, net

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
North American Pharmaceutical—$313.0M———$443.0M

Claims and litigation charges

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
North American Pharmaceutical Segment and Corporate Expenses$14.3M$14.3M————

Gain from cost and equity method investments

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Oncology & Multispecialty———$51.0M——

Integration-related cost, expense

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Oncology & Multispecialty——$24.0M$24.0M$24.0M$24.0M

Restructuring Reserve

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Oncology & Multispecialty—$0.0———$0.0

Restructuring Reserve, Settled without Cash

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Oncology & Multispecialty$250.0K$250.0K$0.0$0.0$0.0$0.0